Burosumab

Therapeutic indications

Burosumab is indicated for:

X-linked hypophosphataemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Burosumab is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Burosumab is contraindicated in the following cases:

Lactation

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)
End stage kidney disease

Phosphate, vitamin D analogues

at least one of
Phosphorus
Phosphoric acid
Vitamin D and analogues
Aluminium phosphate
Calcium phosphate
Magnesium phosphate
Sodium phosphate
Aluminium phosphate
Calcium phosphate
Potassium phosphate
Sodium phosphate

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: CRYSVITA Solution for injection
Summary of Product Characteristics (SPC) 2024: CRYSVITA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈